Clinical Trial

Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies

Study acronym: PREDI-CGRP
Recruiting
View on ClinicalTrials.gov →
Summary
Being able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-10; most recent amendment 2026-06-30.
Trial Details
NCT Number NCT06459648
Lead Sponsor Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Conditions Migraine
Enrollment 350 participants
Start Date 2023-04-26
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-02